MIGS-cataract combination surgery demand — the simultaneous phacoemulsification with iStent inject, Hydrus, Kahook Dual Blade, or OMNI during cataract surgery creating IOP reduction and medication reduction in patients with concurrent cataract and mild-to-moderate glaucoma representing the largest procedural volume segment in the global minimally invasive glaucoma surgery device market — creates the most surgically synergistic market segment, with the Minimally Invasive Glaucoma Surgery Device Market reflecting combination surgery as the premium cataract-integrated commercial driver.

Cataract-glaucoma epidemiological overlap — the approximately 24 million Americans with cataracts, 3.4 million with glaucoma, and 20-30% of cataract patients having concurrent glaucoma or ocular hypertension creating the combined disease prevalence — demonstrates the overlap. The cataract surgery alone reducing IOP by 2-4 mmHg via improved outflow facility, with MIGS adding 4-6 mmHg additional reduction creating the additive benefit.

Medication burden and adherence in glaucoma — the average glaucoma patient using 2-3 medications, 30-50% non-adherent to prescribed regimen, $500-1,000 annual medication cost, and medication side effects (hyperemia, discomfort, cost) creating the treatment burden — demonstrates the adherence challenge. The MIGS-cataract combination's ability to reduce medication burden by 40-60%, improve quality of life, and achieve target IOP with fewer drops creating the patient value proposition.

Surgeon efficiency and operating room optimization — the 5-10 minute additional surgical time for MIGS during cataract surgery, same reimbursement as standalone cataract (CPT 66982/66984), with add-on device reimbursement (CPT 0191T) creating the financial and operational efficiency — demonstrates the workflow integration. The combination's ability to address two diseases in one procedure, reduce future glaucoma progression risk, and avoid separate MIGS surgery creating the clinical efficiency.

Do you think all cataract patients with ocular hypertension or mild glaucoma will eventually receive prophylactic MIGS, or will the cost, uncertain long-term benefit in pre-perimetric disease, and surgeon preference for selective intervention maintain MIGS for established glaucoma with cataract surgery alone for ocular hypertension?

What MIGS devices are approved for combination with cataract surgery? Trabecular bypass: Glaukos iStent inject — Combined with cataract (FDA 2018); Two stents; Phaco + iStent; iStent inject W — Same; Pre-loaded; Alcon Hydrus Microstent — Combined with cataract (FDA 2018); 8 mm nitinol; Phaco + Hydrus; Trabecular ablation/incision: Kahook Dual Blade — Trabecular incision; Combined with cataract; OMNI (Sight Sciences) — Viscodilation + trabeculotomy; Combined with cataract; Trabectome — Trabecular ablation; Combined with cataract; Suprachoroidal: iStent Supra — Limited combination data; Xen Gel Stent — Combined with cataract; Subconjunctival drainage; Outcomes: IOP reduction: Cataract alone: 2-4 mmHg; Cataract + MIGS: 6-10 mmHg; MIGS alone: 7-9 mmHg; Medication reduction: Cataract alone: 10-20%; Cataract + MIGS: 40-60%; MIGS alone: 30-50%; Visual acuity: Cataract + MIGS: equivalent to cataract alone; Safety: Cataract + MIGS: similar to cataract alone; Additional MIGS risks: minimal; Procedure details: Time: Phaco: 15-20 minutes; MIGS: 5-10 minutes additional; Total: 20-30 minutes; Anesthesia: Topical + intracameral; Same as cataract; Incision: Phaco: 2.2-2.4 mm; MIGS: same or additional; IOL: Standard monofocal, toric, multifocal; No MIGS restriction; Postoperative: Drops: Same as cataract; Additional steroid if needed; Follow-up: Day 1, week 1, month 1; Same as cataract; Reimbursement: CPT 66982/66984 — Phaco (same); CPT 0191T — iStent/Hydrus; $800-1,200 physician; Facility: $2,000-4,000; Medicare: covered; Commercial: generally covered; Patient selection: Cataract + mild OAG: Primary indication; Cataract + moderate OAG: Good candidate; Cataract + severe OAG: Consider trabeculectomy; Ocular hypertension: Off-label, debated; Angle-closure: Not appropriate; Neovascular: Not appropriate; Contraindications: Active uveitis; Angle closure; Neovascular glaucoma; Prior failed trabecular surgery; Severe endothelial compromise.

What is the market size and surgical volume for combination MIGS? Market metrics: Combination MIGS: $400-600 million (2024); 50-60% of MIGS device market; Standalone MIGS: 30-40%; Other: 5-10%; Cataract surgery volume: US: 4 million annually; Michigan: 100,000-120,000; Combination penetration: 15-20% of cataract patients with glaucoma/OHT; 600,000-800,000 US annually; 15,000-20,000 Michigan; Growth: 10-12% CAGR; Key suppliers: Glaukos — iStent inject, 40-45% combination; Alcon — Hydrus, 20-25%; Sight Sciences — OMNI, 8-10%; NeoMedix — Trabectome, 3-5%; New World Medical — Kahook, 3-5%; Others — 5-10%; Market drivers: Cataract volume, aging population, glaucoma prevalence, medication burden, patient preference, surgeon adoption, reimbursement, safety profile, efficiency; Challenges: Cost, long-term durability, patient selection, refractory cases, standalone vs. combination, reimbursement parity, competition with SLT, medication persistence; Trends: Earlier intervention, standalone expansion, multiple MIGS, personalized approach, AI patient selection, sustained drug delivery, premium IOL compatibility, telemedicine, patient-reported outcomes.

#MIGS #CataractSurgery #CombinationSurgery #PhacoMIGS #iStentInject #Hydrus #GlaucomaCataract #OphthalmologySurgery #IOPReduction